Furosemide versus mannitol in patients who received cisplatin-based chemotherapy using short hydration: study protocol for a randomized controlled trial
Abstract Background: Cisplatin (CDDP) is a key drug for various thoracic malignancies. To avoid renal toxicity of CDDP, mannitol is routinely used, but it reportedly causes phlebitis. Furosemide is another widely-used option for diuresis, but to date, it has not been assessed in comparison with mannitol. We therefore undertake a randomized phase II comparative study of furosemide and mannitol in CDDP-based chemotherapy using short hydration. Methods: This study is designed as a two-arm, prospective, randomized, single-center, open-label phase II study. The primary endpoint is set as the proportion of patients who experienced any grade renal dysfunction, defined as elevation in creatinine using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, during the first cycle. Secondary endpoints are: the proportion of patients who experienced ≥ grade 2 renal dysfunction during the first cycle, any grade and ≥ grade 2 renal dysfunction after the completion of forth cycle, and the proportion of patients who had phlebitis. A total of 105 patients will be enrolled in this trial. Discussion: The results of this study will suggest that furosemide can be better choice than mannitol regarding convenience and in reduction of phlebitis. Trial registration: University Hospital Medical Information Network Clinical Trials Registry, ID: UMIN000031910(http://www.umin.ac.jp/ctr/index.htm). Registered on 1 April 2018.